DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of market expansion services for pharmaceutical, over-the-counter (OTC), consumer health, and medical device companies, along with Chiesi, an international biopharmaceutical group, have secured approval to introduce a rare ophthalmic disease medication in a key Asian market.
The development enhances access to treatment for patients with rare ophthalmic diseases. DKSH Business Unit Healthcare has recently accelerated access to an ophthalmic treatment by securing national reimbursement in just 10 months, significantly ahead of the typical 18-month timeframe.
By removing affordability barriers, this milestone not only enables patients to access treatment more quickly, but also improves their quality of life. Including rare disease medications in the national reimbursement list ensures that vital treatment options are accessible to more individuals affected by rare diseases.
Ensuring the availability and access to medication enables efforts to address often-overlooked ophthalmic diseases. Asian populations are generally more predisposed to eye diseases, including rare ophthalmic conditions, for which treatments are often limited, with some conditions having only a singular treatment option. This outcome sets a new precedent for future rare disease medication approvals and underscores the importance of partnerships and shared urgency in the healthcare ecosystem.
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases.
